Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

SZSE:002399 Stock Report

Market Cap: CN¥13.0b

Shenzhen Hepalink Pharmaceutical Group Balance Sheet Health

Financial Health criteria checks 5/6

Shenzhen Hepalink Pharmaceutical Group has a total shareholder equity of CN¥12.1B and total debt of CN¥4.9B, which brings its debt-to-equity ratio to 40%. Its total assets and total liabilities are CN¥18.9B and CN¥6.7B respectively.

Key information

40.0%

Debt to equity ratio

CN¥4.86b

Debt

Interest coverage ration/a
CashCN¥2.50b
EquityCN¥12.14b
Total liabilitiesCN¥6.74b
Total assetsCN¥18.87b

Recent financial health updates

Recent updates

Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Jun 12
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues

May 06
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues

Financial Position Analysis

Short Term Liabilities: 002399's short term assets (CN¥10.4B) exceed its short term liabilities (CN¥4.6B).

Long Term Liabilities: 002399's short term assets (CN¥10.4B) exceed its long term liabilities (CN¥2.1B).


Debt to Equity History and Analysis

Debt Level: 002399's net debt to equity ratio (19.4%) is considered satisfactory.

Reducing Debt: 002399's debt to equity ratio has reduced from 62.4% to 40% over the past 5 years.

Debt Coverage: 002399's debt is well covered by operating cash flow (30.7%).

Interest Coverage: Insufficient data to determine if 002399's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies